Description
Product Specifications
- Product: DSIP 10mg
- Compound / formulation: Delta Sleep-Inducing Peptide
- Labeled quantity / volume: 10mg per vial
- Physical form: White lyophilized powder
- Research focus: Sleep–wake regulation, sleep-stage research, neurobehavioral signaling
- Available batch identifiers: Red cap / green collar, lot DS10-0918 (submitted sample photo, report #238262)
- SKU: HOP-DSIP-10MG
- Intended classification: Laboratory research only
Independent Laboratory Testing
Red cap / green collar — Janoshik, report #238262 — Batch DS10-0918
- Compound reported: DSIP
- Measured content: 11.39mg; 11.44mg; 11.39mg
- Purity: 99.156%; 99.121%; 99.130%
- Test date: October 1, 2026
- Verification key: XIS2WGLKEYLU
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Additional Product Details
- Catalog availability: Out of stock
Scientific Research Background
Sleep is an essential biological process. During the night, the brain moves through different stages of sleep, while the body regulates functions associated with rest, alertness, and daily rhythms.
Scientists study these patterns to understand why people fall asleep, why they wake up, and what happens when normal sleep becomes disrupted.
Delta sleep-inducing peptide (DSIP) is a short peptide consisting of nine amino acids. Its name reflects early research investigating whether it could influence slow-wave sleep, a stage of non-rapid-eye-movement (NREM) sleep associated with prominent slow electrical activity in the brain.
However, a compound’s name does not establish what it reliably does.
Beginning in the late 1970s and early 1980s, researchers investigated DSIP in experimental models and small human studies. Some early investigations reported changes in sleep duration, the time needed to fall asleep, or the continuity of sleep.
Other studies found weaker effects or concluded that observed improvements were unlikely to provide meaningful clinical benefit.
This distinction is important. Sleep can be evaluated through several different measurements, and an improvement in one measurement does not necessarily mean that someone experiences better overall sleep.
Published research on DSIP remains limited, much of it dates back several decades, and its biological mechanisms are not fully established.
Compound details
- Peptide length: Nine amino acids
- Research classification: Peptide
Clinical Research Observations
1. Why did scientists begin studying DSIP?
Sleep is not simply a period when the brain switches off. It involves organized changes in brain activity that repeat throughout the night.
Researchers have long investigated whether naturally occurring substances help regulate those changes.
What researchers found: Early experimental work led scientists to investigate DSIP as a possible participant in sleep regulation. This prompted laboratory studies and small human experiments examining sleep patterns.
Why it matters: Identifying a substance associated with sleep is a starting point for research. It does not establish that supplying more of that substance reliably improves sleep.
2. Did early human studies find changes in sleep?
Researchers can measure sleep using recordings of brain activity, eye movements, and muscle activity. These measurements help distinguish sleep stages and determine how long a person remains asleep.
In a small 1981 study, six healthy volunteers participated in a double-blind crossover experiment, meaning participants received both DSIP and placebo under controlled conditions.
What researchers found: Investigators reported increased sleep during an observation period after DSIP exposure and changes in some measurements during the following night’s sleep.
Why it matters: These results encouraged further investigation. However, a study involving only six people cannot establish reliable benefits for a broader population.
3. What did researchers find in people with insomnia?
Insomnia can involve difficulty falling asleep, waking repeatedly, or being unable to maintain sleep long enough to feel rested.
Researchers investigated whether DSIP could influence these problems.
What researchers found: Some small studies involving people with chronic insomnia reported improvements in selected sleep measurements. For example, a 1987 placebo-controlled study involving 14 participants reported changes in nighttime sleep and daytime performance.
Why it matters: These findings suggested that DSIP warranted additional study. They did not establish that the effects would be consistent across larger groups or sustained over time.
4. Did later studies confirm those early findings?
Early research sometimes produces encouraging results that become less convincing when investigators conduct additional controlled studies.
This is one reason scientists examine the same question using different study designs.
What researchers found: A 1987 study of patients with chronic insomnia found that several apparent improvements were not significantly different from placebo or baseline measurements. The investigators concluded that the observed sleep improvement had little clinical significance.
Why it matters: An improvement observed during a study does not necessarily mean the investigated compound caused it. Placebo comparisons help researchers distinguish treatment effects from ordinary variation.
5. What did a later double-blind study show?
Researchers continued investigating DSIP to determine whether its effects could be measured consistently.
In 1992, investigators studied 16 people with chronic insomnia using a double-blind, placebo-controlled design.
What researchers found: Some objective measurements, including sleep efficiency and the time needed to fall asleep, appeared better in the DSIP group. However, the investigators considered these effects weak, potentially influenced by changes in the placebo group, and unlikely to offer major therapeutic benefit. Subjective sleep quality did not improve.
Why it matters: This study illustrates the difference between detecting a small change in a sleep measurement and demonstrating a meaningful improvement in a person’s sleep experience.
6. Does DSIP reliably increase deep sleep?
Deep sleep is commonly associated with slow-wave activity during NREM sleep. It is only one component of normal sleep.
Researchers evaluate sleep quality using several measures rather than treating deep sleep as the only important outcome.
What researchers found: In a 1981 study involving six healthy volunteers, researchers reported less time in light stage 1 sleep, among other changes. However, this finding does not demonstrate a consistent increase in deep sleep. A separate 1987 controlled study found that several observed changes in sleep measurements were not statistically significant compared with placebo or baseline.
Why it matters: DSIP’s name should not be interpreted as proof that it consistently increases deep sleep. The available studies do not establish that effect.
7. What is the overall scientific takeaway?
DSIP attracted scientific interest because early experiments suggested that it might influence sleep regulation.
Small human studies subsequently produced mixed results. Some reported changes in selected sleep measurements, while others found weak effects, inconsistent findings, or little meaningful benefit.
What researchers found: The historical evidence does not provide a consistent demonstration that DSIP produces clinically important improvements in insomnia or sleep quality. The studies were generally small and do not establish a reliable human safety or effectiveness profile for current research products.
Why it matters: DSIP remains a subject of scientific investigation rather than an established sleep treatment. Findings involving previously studied preparations cannot automatically be applied to this particular research product.
Published Scientific Research
The following publications provide historical scientific context for DSIP. They do not establish the analytical characteristics, safety, or effectiveness of House of Peptides’ DSIP 10mg.
- Schneider-Helmert et al. (1981) — Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy and Toxicology. A double-blind crossover study involving six healthy volunteers reported changes in selected sleep measurements. PubMed — PMID 6895513. Supports: Clinical Question 2.
- Schneider-Helmert (1987) — Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. A placebo-controlled study involving 14 participants reported improvements in selected nighttime sleep and daytime performance measurements. PubMed — PMID 3622582. DOI:
10.1159/000116143. Supports: Clinical Question 3. - Monti et al. (1987) — Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research. Reported limited differences from placebo and concluded that observed sleep improvements had little clinical significance. PubMed — PMID 3583493. Supports: Clinical Questions 4 and 6.
- Bes et al. (1992) — Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. A study involving 16 participants found weak changes in selected objective measurements without meaningful improvement across most other outcomes. PubMed — PMID 1299794. DOI:
10.1159/000118919. Supports: Clinical Questions 5 and 7.
Evidence boundary: These publications describe small historical human studies. Their findings are mixed, and they do not establish that DSIP is an effective treatment for insomnia or that this research product is equivalent to the preparations investigated.
Understanding the Research Findings
DSIP has been investigated for its possible relationship with sleep regulation and the organization of the sleep–wake cycle.
Early human studies reported changes in selected measurements, but later investigations produced inconsistent findings and questioned their clinical significance.
The available research does not establish reliable improvements in sleep quality, deep sleep, or insomnia symptoms.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.